Mucus forms the first defense line of human lungs, and as such hampers the efficient delivery of therapeutics to the underlying epithelium. This holds particularly true for genetic cargo such as CRISPR-based gene editing tools which cannot readily surmount the mucosal barrier. While lipid nanoparticles (LNPs) emerged as versatile non-viral gene delivery systems that could help overcome the delivery challenge, many knowledge gaps remain, especially for diseased states such as cystic fibrosis (CF). This study provides fundamental insights into Cas9 mRNA or ribonucleoprotein-loaded LNP-mucus interactions in healthy and diseased states by assessing the impact of the genetic cargo, mucin sialylation, mucin concentration, ionic strength, pH, and polyethylene glycol (PEG) concentration and nature on LNP diffusivity leveraging experimental approaches and Brownian dynamics simulations. Taken together, this study identifies key mucus and LNP characteristics that are critical to enabling a rational LNP design for transmucosal delivery. Graphical Abstract
Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions
Belal Tafech,M. Rokhforouz,Jerry Leung,Molly M H Sung,Paulo J C Lin,Don D Sin,D. Lauster,Stephan Block,Bradley S. Quon,Ying K. Tam,P. Cullis,James J. Feng,S. Hedtrich
Published 2024 in bioRxiv
ABSTRACT
PUBLICATION RECORD
- Publication year
2024
- Venue
bioRxiv
- Publication date
2024-01-22
- Fields of study
Biology, Medicine, Environmental Science
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-93 of 93 references · Page 1 of 1
CITED BY
Showing 1-27 of 27 citing papers · Page 1 of 1